The Glivec® International Patient Assistance Program (GIPAP) is one of the most comprehensive and far-reaching cancer access programs ever developed on a global scale.
Novartis designed GIPAP to provide Glivec (imatinib) free of cost to eligible patients in developing countries who meet specific medical and socio-economic guidelines. Through The Max Foundation, GIPAP also provides information and referral assistance to patients, their family members and caregivers.
GIPAP is more than a drug donation program; its goal is to optimize successful Glivec treatment by providing patients with emotional support and increasing awareness within their communities.
The Max Foundation, as Novartis’ main partner in the administration of GIPAP, provides socio-economic evaluation of patients, guides physicians through the patient evaluation process, and provides emotional support, information and referral assistance to patients, their family members and care givers. In addition, we monitor patients to support the highest standard of patient care, collaborate with Novartis to identify and qualify eligible medical centers and physicians worldwide, and protect confidential patient information and data received in the course of program administration.
Through The Max Foundation’s partnership with Novartis, experienced physicians and local organizations, GIPAP has been able to reach patients who would otherwise not have access to Glivec for their life-threatening diseases.
What is GIPAP?
For its breakthrough cancer therapy Glivec, Novartis designed The Glivec® International Patient Assistance Program, or GIPAP, one of the most comprehensive and far-reaching cancer access programs ever developed on a global scale. The "direct-to-patient” model is designed to provide the drug directly to individual patients by their treating physicians.
Since its implementation in early 2002, GIPAP has provided Glivec to more than 19,000 patients in 80 developing countries with minimal reimbursement capabilities who would not otherwise have access to the drug to treat their life-threatening diseases. Currently, there is no other global cancer program like it in existence. Its success is due in large part to its ability to adapt program goals to local rules/ regulations.
GIPAP is accessible to eligible patients who:
Unlike traditional donation programs that deliver drugs through hospitals or other third party distribution organizations, Glivec is delivered/dispensed directly to patients by their treating physician/pharmacist.
As Novartis’ main partner in the administration of GIPAP, The Max Foundation is responsible for reviewing and verifying patients’ eligibility according to specific medical requirements provided by Novartis and performing socio-economic evaluations. These requirements are in line with World Health Organization (WHO) guidelines, which provide global guidance on charitable donation programs. Novartis is responsible for identifying qualified medical centers and physicians, and for donating and supplying Glivec to qualified treatment centers that provide the drug to those patients approved by The Max Foundation.
To qualify to administer GIPAP, a qualified center must be able to fulfill the following conditions:
Novartis may not qualify a Center or a physician meeting the above-mentioned criteria if the country has already enough Qualified Centers/physicians or for non- compliance reasons
In countries where Novartis Oncology does not have a local presence, Novartis partners with The Max Foundation and with Axios International to administer GIPAP.
Axios assists private and public organizations in creating and implementing practical healthcare programs in the developing world.
Qualification Requirements for GIPAP
In order to qualify for GIPAP, the patient must meet specific eligibility criteria in medical and socio-economic areas as required by Novartis. GIPAP requirements were developed in line with WHO guidelines on access to medicines.